Table 5 Comparison of changes in outcome measurements between patients who received Dangguixu-san and those who received placebo for grade I acute lateral ankle sprain (n = 23)
From: Effects of Dangguixu-san in patients with acute lateral ankle sprain: a randomized controlled trial
Dependent variables | Group (n) | Week 0 (M ± SD) | Week 1 (M ± SD) | Week 5 (M ± SD) | Difference (w1–w0) | Z (p)a | Difference (w5–w0) | Z (p)a | Difference (w5–w1) | Z (p)a |
|---|---|---|---|---|---|---|---|---|---|---|
VAS of pain | DS (n = 12) | 39.33 ± 14.51 | 19.50 ± 11.70 | 16.67 ± 21.46 | − 19.83 ± 15.02 | − 0.31 (0.755) | − 22.67 ± 24.64 | − 0.56 (0.577) | − 2.83 ± 20.66 | − 0.32 (0.750) |
Placebo (n = 11) | 43.91 ± 21.19 | 22.82 ± 12.24 | 14.73 ± 10.56 | − 21.09 ± 15.00 | −29.18 ± 19.81 | −8.09 ± 8.62 | ||||
Degree of edema | DS (n = 12) | 0.17 ± 0.39 | 0.17 ± 0.58 | 0.25 ± 0.45 | 0.03 ± 0.36 | − 0.24 (0.812) | 0.03 ± 0.45 | − 0.79 (0.431) | 0.00 ± 0.67 | − 0.69 (0.488) |
Placebo (n = 11) | 0.09 ± 0.54 | 0.09 ± 0.30 | 0.00 ± 0.00 | − 0.06 ± 0.24 | −0.08 ± 0.25 | −0.02 ± 0.26 | ||||
TOTAL EQ-5D-5L | DS (n = 12) | 9.33 ± 1.78 | 7.08 ± 1.56 | 7.50 ± 3.66 | − 2.25 ± 1.82 | − 0.84 (0.399) | − 1.83 ± 3.90 | − 0.77 (0.439) | 0.42 ± 4.10 | − 0.51 (0.609) |
Placebo (n = 11) | 10.73 ± 2.90 | 7.73 ± 1.49 | 7.18 ± 1.89 | − 3.00 ± 2.10 | − 3.55 ± 3.83 | − 0.55 ± 2.62 | ||||
TOTAL FAOS | DS (n = 12) | 349.28 ± 60.85 | 393.40 ± 51.89 | 403.23 ± 98.09 | 44.13 ± 52.35 | − 0.19 (0.854) | 53.95 ± 86.99 | − 1.05 (0.295) | 9.83 ± 100.83 | − 0.86 (0.389) |
placebo (n = 11) | 314.15 ± 88.63 | 376.45 ± 62.75 | 410.71 ± 63.41 | 62.31 ± 84.87 | 96.56 ± 106.41 | 34.25 ± 60.46 |